This study aims to provide long-term follow-up for participants who received the LX2020 gene therapy for arrhythmogenic cardiomyopathy (a disease of the heart muscle) caused by a disease-causing variant in the PKP2 (plakophilin-2) gene. It can include people who previously received this gene therapy in the LX2020-01 study. This is a non-phase study and is enrolling participants by invitation.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Participants who received LX2020 in study LX2020-01 Exclusion Criteria: * Concurrent enrollment in any other clinical investigation involving use of an investigational agent.